Metraipolis › archive › dc_fe3aaef353ba

Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of… — Europe PMC PMID:42449661

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42449661
DOI: 10.3390/cancers18132118
License (as archived): solo-consultazione
Archived: 2026-10-31T06:41:12.036Z
SHA-256 of the archived text: cfa39bf7d76b2596c5355e96e53cce11ca0beba4772ceaf8594c9c47b19e10d0
Stable URL of this page: https://metraipolis.com/documento/dc_fe3aaef353ba

How to cite

Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of… — Europe PMC PMID:42449661 — Europe PMC (en), https://europepmc.org/article/MED/42449661 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe3aaef353ba (Metraipolis archive dc_fe3aaef353ba, sha256 cfa39bf7d76b2596c5355e96e53cce11ca0beba4772ceaf8594c9c47b19e10d0)

BibTeX

@misc{dcfe3aaef353ba,
  title = {Comprehensive Safety and Efficacy Evaluation of Immunotherapy Combination Approaches Versus Tyrosine Kinase Inhibitor Monotherapy as First-Line Treatment of… — Europe PMC PMID:42449661},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42449661},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe3aaef353ba; sha256 cfa39bf7d76b2596c5355e96e53cce11ca0beba4772ceaf8594c9c47b19e10d0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42449661. Agents can read the archived copy with the MCP tool read_document.